Marinus Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Marinus Pharmaceuticals's earnings have been declining at an average annual rate of -10.4%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 62% per year.
Key information
-10.4%
Earnings growth rate
22.5%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 62.0% |
Return on equity | -843.5% |
Net Margin | -456.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?
Nov 04Marinus Pharmaceuticals (MRNS) Investor Presentation - Slideshow
May 26We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely
Apr 14Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Intrinsic Value Is Potentially 53% Above Its Share Price
Mar 10Revenue & Expenses BreakdownBeta
How Marinus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 31 | -141 | 61 | 0 |
30 Sep 23 | 31 | -134 | 60 | 0 |
30 Jun 23 | 26 | -28 | 59 | 10 |
31 Mar 23 | 22 | -35 | 60 | 0 |
31 Dec 22 | 25 | -20 | 57 | 0 |
30 Sep 22 | 20 | -14 | 55 | 0 |
30 Jun 22 | 28 | -105 | 49 | 0 |
31 Mar 22 | 28 | -91 | 39 | 0 |
31 Dec 21 | 15 | -99 | 37 | 0 |
30 Sep 21 | 15 | -88 | 31 | 0 |
30 Jun 21 | 5 | -84 | 28 | 0 |
31 Mar 21 | 4 | -76 | 26 | 0 |
31 Dec 20 | 2 | -76 | 19 | 0 |
30 Sep 20 | 0 | -74 | 16 | -2 |
30 Jun 20 | 0 | -72 | 14 | -18 |
31 Mar 20 | 0 | -69 | 13 | -9 |
31 Dec 19 | 0 | -54 | 12 | 0 |
30 Sep 19 | 0 | -49 | 11 | 10 |
30 Jun 19 | 0 | -46 | 11 | 36 |
31 Mar 19 | 0 | -43 | 9 | 33 |
31 Dec 18 | 0 | -37 | 9 | 28 |
30 Sep 18 | 0 | -31 | 8 | 23 |
30 Jun 18 | 0 | -24 | 8 | 17 |
31 Mar 18 | 0 | -19 | 7 | 12 |
31 Dec 17 | 0 | -19 | 7 | 12 |
30 Sep 17 | 0 | -20 | 7 | 13 |
30 Jun 17 | 0 | -22 | 7 | 15 |
31 Mar 17 | 0 | -27 | 7 | 20 |
31 Dec 16 | 0 | -29 | 7 | 22 |
30 Sep 16 | 0 | -30 | 6 | 24 |
30 Jun 16 | 0 | -29 | 6 | 22 |
31 Mar 16 | 0 | -25 | 6 | 19 |
31 Dec 15 | 0 | -25 | 6 | 19 |
30 Sep 15 | 0 | -21 | 6 | 15 |
30 Jun 15 | 0 | -18 | 5 | 13 |
31 Mar 15 | 0 | -17 | 4 | 12 |
31 Dec 14 | 0 | -13 | 3 | 9 |
30 Sep 14 | 0 | -12 | 2 | 8 |
30 Jun 14 | 0 | -12 | 2 | 7 |
31 Mar 14 | 0 | -11 | 2 | 6 |
Quality Earnings: MRNS is currently unprofitable.
Growing Profit Margin: MRNS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRNS is unprofitable, and losses have increased over the past 5 years at a rate of 10.4% per year.
Accelerating Growth: Unable to compare MRNS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRNS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-14.6%).
Return on Equity
High ROE: MRNS has a negative Return on Equity (-843.45%), as it is currently unprofitable.